From Regulation to Reality: The Implementation Test for New Genomic Techniques

More than seven years after my first encounter with this dossier—back when we called it (vintage feel now!) “#NewBreedingTechniques”—it is almost surreal to see a regulation number and title attached to something that, for so long, existed mainly in policy discussions and in the hopes of those who supported it from day one.

#NGTs expand the toolbox available to plant breeders, making it possible to develop traits such as disease and pest resistance, or drought tolerance, at a pace conventional breeding often cannot match in a changing climate. They are not a silver bullet, but together with other emerging technologies, they can become an important driver of agricultural innovation.

But adoption is not the same as application. The relief of finally seeing a regulation set in stone is not the same as seeing the regulatory framework deliver in practice. The next two years will determine whether the new legislation becomes a workable route for innovation—or another technically sound idea slowed by procedural uncertainty.

Regulation (EU) 2026/1388 entered into force on 16 July 2026 and will apply from 17 July 2028. Between those dates lies the real implementation test: translating the distinction between Category 1 and Category 2 NGT plants into evidence requirements, verification procedures, risk-assessment methodologies and analytical standards that operators and authorities can apply consistently. This is the scope of the Implementation Strategy as published by the Commission.

The delegated act under Article 25 will be central to Category 1. It must specify the information needed to demonstrate that a plant is an NGT plant and how a requester can show compliance with the Annex I equivalence criteria and the trait-based exclusion. It will also shape the preparation of verification requests, the submission of patent and licensing information, national verification reports, and the decisions declaring Category 1 status.

That may sound procedural, but it defines the regulatory boundary on which research and breeding investments will depend. Category 1 verification will operate partly at national level and partly at EU level. Comparable evidence requirements and a shared interpretation of the equivalence criteria will therefore be essential if the same plant is to receive consistent treatment across the Union.

For Category 2, the implementing act under Article 27 will specify the adapted environmental and food-and-feed safety assessments; the preparation of notifications and applications; the conditions for exemption from post-market environmental monitoring; and the arrangements for analytical-method performance where identification or quantification is not technically feasible. Here, flexibility is both the promise and the risk. Tailoring requirements to the characteristics of a Category 2 plant can make the system more proportionate. But flexibility without clear grounds, evidence standards and agreed methodologies can produce divergent interpretations—and delay.

Why the guidance layer matters

EFSA will provide the scientific foundation. Its guidance is expected to explain the scientific and technical detail needed for Category 1 verification and Category 2 notifications, applications and adapted risk assessments. This includes molecular evidence, genetic information, methodologies and quality standards, as well as the evidence needed to justify an exemption from post-market environmental monitoring.

The Commission’s Joint Research Centre, in its role as the European Union Reference Laboratory for GM Food and Feed, will address the analytical dimension. Assisted by the European Network of GMO Laboratories, it will develop guidance on sampling, detection, identification and quantification for Category 2 plants, including adapted arrangements for cases in which conventional analytical requirements cannot be met (and this very point deserves another follow-up post).

This is not a marginal laboratory issue. It connects authorisation with official controls, enforceability and confidence in the system. Put simply: EFSA will help determine what must be scientifically assessed and demonstrated; the JRC will help establish what can be detected, measured and enforced in practice.

The implementation strategy also foresees information for operators on support for NGT research and development, including relevant programmes, financial mechanisms and policies, building on the EU’s Biotech and Biomanufacturing Hub. That is useful, but information about funding opportunities will translate into investment only if the regulatory pathway is sufficiently clear and predictable.

The timetable is certainly ambitious. Calls for evidence are envisaged from Q3/Q4 2026, followed by feedback on the draft acts in 2027 and the adoption of both acts in Q1 2028. EFSA and EURL guidance must be ready by the application date, although it can only be finalised coherently once the delegated and implementing acts have been settled.

The real test

The next phase is therefore not a footnote to the political agreement. It is where the promise of the Regulation will be tested.

Success should be measured not only by whether every instrument is adopted on time, but by whether applicants understand what evidence is required, authorities reach consistent decisions, analytical limitations are addressed transparently, and researchers and breeders can plan with confidence.

Europe has created a new legal framework for NGT plants. Now it must build the operating system.

Originally published on LinkedIn

#NewGenomicTechniques #NGT #EUPolicy #PlantBreeding #Biotech #FoodLaw #Innovation #EFSA #JRC